Dr Gennari’s areas of expertise include diagnostic and therapeutic innovation in breast cancer. Her current research is focused on the identification of individual drug responsiveness in breast tumors and therapy optimization in metastatic breast cancer. Other active research areas include the evaluation of host metabolism in breast cancer, functional imaging by PET-CT with 18F-FES to evaluate endocrine responsiveness in triple negative advanced breast cancer and identification of predictive factors of responsiveness to immunotherapy in advanced breast cancer.

She is the PI and Coordinator of the ERA-NET JTC 2011 project (European TRANSCAN project) – Early prediction of efficacy of endocrine therapy in breast cancer: pilot study and validation with 18F Fluoroestradiol (ET-FES project). She is also expanding research interests in immunotherapy and response prediction in BC. She acts as referee for numerous high-profile oncology journals, and has authored more than 90 peer-reviewed publications as well as numerous book chapters, abstracts, and other articles.

She is member of ASCO, ESMO and AIOM. She has served as international reviewer for the French National Cancer Institute (INCA), France (2010-2013). She is member of the Editorial Team (Clinical Editor) of the Cochrane Breast Cancer Group. From 2014 to 2018 she has been member of the Technical Scientific Committee (CTS) of IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO IST, Genova, IT. She is member of the ABC (Advanced Breast Cancer) International Consensus Panel. – ESMO faculty member for the Breast cancer faculty group since 2017. She has served as Chair or Co-Chair of symposia in international conferences, organized by ESMO, ECCO and EBCC.